Key Updates in AxSpA From EULAR 2025

Updates in AxSpA from EULAR 2025 include 3-year data for bimekizumab, definition of difficult-to-manage subgroups, effectiveness of a digital therapeutic app, and a potential cell-therapy approach.Medscape